Vident Advisory LLC Acquires 33,415 Shares of Haleon plc (NYSE:HLN)

Vident Advisory LLC grew its position in Haleon plc (NYSE:HLN - Free Report) by 99.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,066 shares of the company's stock after acquiring an additional 33,415 shares during the period. Vident Advisory LLC's holdings in Haleon were worth $640,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of HLN. Sierra Ocean LLC bought a new position in Haleon in the 4th quarter worth approximately $26,000. Geneos Wealth Management Inc. bought a new position in Haleon in the 4th quarter worth approximately $35,000. FIL Ltd raised its position in Haleon by 45.7% in the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after purchasing an additional 1,270 shares during the last quarter. Spire Wealth Management bought a new position in Haleon in the 4th quarter worth approximately $39,000. Finally, Addison Advisors LLC raised its position in Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after purchasing an additional 1,106 shares during the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Stock Up 0.9%

HLN traded up $0.10 during trading on Tuesday, hitting $11.24. The company had a trading volume of 15,185,663 shares, compared to its average volume of 8,272,818. The company has a market capitalization of $50.66 billion, a PE ratio of 33.06, a PEG ratio of 2.82 and a beta of 0.24. Haleon plc has a one year low of $8.25 and a one year high of $11.35. The firm's 50-day moving average price is $10.33 and its 200 day moving average price is $9.93. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The firm had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, equities analysts expect that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The business also recently declared a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. Haleon's dividend payout ratio is 58.97%.

Analyst Upgrades and Downgrades

A number of analysts have commented on HLN shares. Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price for the company in a report on Friday, May 9th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Finally, BNP Paribas Exane raised shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target for the company in a report on Tuesday. Six research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Haleon has an average rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.